INHA and breast carcinoma: In summary INHA, INHBA, TGFBR3, and ENG display clear discrepant profiles of expression among responders and non-responders to both anthracycline and taxane chemotherapy for distinct breast cancer subtypes, specifically luminal A, and serous ovarian cancer.